← Back to Screener
Charles River Laboratories International, Inc. (CRL)
Price$185.54
Favorite Metrics
Price vs S&P 500 (26W)1.34%
Price vs S&P 500 (4W)10.22%
Market Capitalization$9.14B
All Metrics
P/CF (Annual)12.39x
Book Value / Share (Quarterly)$64.30
P/TBV (Annual)3.54x
Revenue Growth (3Y)0.33%
Cash Flow / Share (Quarterly)$10.53
Price vs S&P 500 (YTD)-11.96%
Gross Margin (TTM)34.98%
Net Profit Margin (TTM)-3.59%
EPS (TTM)$-2.96
10-Day Avg Trading Volume0.85M
EPS Excl Extra (TTM)$-2.96
Revenue Growth (5Y)6.55%
EPS (Annual)$-2.91
ROI (Annual)-2.72%
Gross Margin (Annual)34.98%
Net Profit Margin (5Y Avg)6.28%
Cash / Share (Quarterly)$4.34
Revenue Growth QoQ (YoY)-0.83%
ROA (Last FY)-2.02%
Revenue Growth TTM (YoY)-0.85%
EBITD / Share (TTM)$4.55
ROE (5Y Avg)8.14%
Operating Margin (TTM)0.63%
Cash Flow / Share (Annual)$10.53
P/B Ratio2.89x
P/B Ratio (Quarterly)3.16x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.76x
Net Interest Coverage (TTM)0.22x
ROA (TTM)-1.94%
EV / EBITDA (TTM)48.96x
EPS Incl Extra (Annual)$-2.91
Current Ratio (Annual)1.29x
Quick Ratio (Quarterly)0.83x
3-Month Avg Trading Volume0.90M
52-Week Price Return76.38%
EV / Free Cash Flow (Annual)21.34x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$57.39
P/S Ratio (Annual)2.28x
Asset Turnover (Annual)0.56x
52-Week High$228.88
Operating Margin (5Y Avg)11.67%
EPS Excl Extra (Annual)$-2.91
CapEx CAGR (5Y)5.64%
Tangible BV CAGR (5Y)16.31%
26-Week Price Return10.09%
Quick Ratio (Annual)0.83x
13-Week Price Return-15.02%
Total Debt / Equity (Annual)0.68x
Current Ratio (Quarterly)1.29x
Enterprise Value$11,063.129
Revenue / Share Growth (5Y)6.99%
Asset Turnover (TTM)0.54x
Book Value / Share Growth (5Y)8.65%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)9.04x
Pretax Margin (Annual)-2.48%
Cash / Share (Annual)$4.34
3-Month Return Std Dev50.65%
Gross Margin (5Y Avg)36.25%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-20.38%
ROE (Last FY)-4.56%
Net Interest Coverage (Annual)0.32x
EPS Basic Excl Extra (Annual)$-2.91
P/FCF (TTM)17.62x
Receivables Turnover (TTM)5.62x
EV / Free Cash Flow (TTM)21.34x
Total Debt / Equity (Quarterly)0.68x
EPS Incl Extra (TTM)$-2.96
Receivables Turnover (Annual)5.62x
ROI (TTM)-2.59%
P/S Ratio (TTM)2.28x
Pretax Margin (5Y Avg)8.63%
Revenue / Share (Annual)$81.01
Tangible BV / Share (Annual)$57.39
Forward P/E16.75x
Free OCF CAGR (5Y)6.41%
Price vs S&P 500 (52W)41.29%
Year-to-Date Return-7.82%
5-Day Price Return3.11%
EPS Normalized (Annual)$-2.91
ROA (5Y Avg)3.18%
Net Profit Margin (Annual)-3.59%
Month-to-Date Return6.60%
Cash Flow / Share (TTM)$15.38
EBITD / Share (Annual)$4.17
Operating Margin (Annual)0.63%
LT Debt / Equity (Annual)0.67x
P/CF (TTM)12.39x
ROI (5Y Avg)4.22%
LT Debt / Equity (Quarterly)0.67x
EPS Basic Excl Extra (TTM)$-2.96
P/TBV (Quarterly)3.54x
P/B Ratio (Annual)3.16x
Inventory Turnover (TTM)9.04x
Pretax Margin (TTM)-2.48%
Book Value / Share (Annual)$64.30
Price vs S&P 500 (13W)-17.89%
Beta1.55x
P/FCF (Annual)17.62x
Revenue / Share (TTM)$81.59
ROE (TTM)-4.40%
52-Week Low$99.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.95
3.91
3.91
3.91
Industry Peers — R&D — Physical Sciences(9)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $185.54 |
IQVIQVIA Holdings Inc. | 22.06x | 22.28% | 7.50% | — | $176.76 |
INCYIncyte Genomics Inc | 15.00x | 29.15% | 14.03% | — | $96.92 |
MEDPMedpace Holdings, Inc. Common Stock | 32.96x | 118.82% | 22.27% | — | $528.44 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.95 |
NRCNational Research Corporation Common Stock (Delaware) | 35.35x | 58.51% | 0.61% | 3.55% | $18.18 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.55 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.86 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.29 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.13 |
About
Charles River Laboratories is a leading provider of drug discovery and development services, operating since 1947. The company's three core segments—research models (supplying genetically characterized animal models for preclinical testing), discovery and safety assessment (early-stage drug development services), and manufacturing support (microbial solutions, in vitro testing, and biologics services)—position it as a critical partner throughout the pharmaceutical development lifecycle.